文献速递类风湿关节炎

类风湿关节炎患者血清25-羟基维生素D与全因死亡率的L型关联

L-shaped association between serum 25-hydroxyvitamin D and all-cause mortality of individuals with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该队列研究纳入2001-14年NHANES中1466例类风湿关节炎患者,分析血清25-羟基维生素D与全因及病因特异性死亡率的关系。随访10453人年期间记录268例全因死亡,发现血清25-羟基维生素D与全因死亡率呈非线性L型关联,在<37.30 nmol/l时降低与全因死亡风险升高显著相关[HR 0.95 (0.92, 0.98); P < 0.01]。

要点

  • 血清25-羟基维生素D与类风湿关节炎患者全因死亡率呈L型关联。
  • 血清25-羟基维生素D <37.30 nmol/l时,降低与全因死亡风险升高显著相关[HR 0.95 (0.92, 0.98); P < 0.01]。
  • 作者认为应将血清25-羟基维生素D提升至一定水平以预防过早死亡。

核心结论

  • 类风湿关节炎患者中血清25-羟基维生素D与全因死亡率呈L型关联,提示应将血清25-羟基维生素D提升至一定水平以预防过早死亡。

研究设计与样本

  • 该队列研究纳入2001-14年美国国家健康与营养调查(NHANES)中1466例类风湿关节炎患者,死亡状态依据国家死亡索引的死亡证明记录获取。
  • 采用Cox比例风险模型估计死亡风险比(HR)及95%CI,并建立广义相加模型、平滑曲线拟合和两段式Cox比例风险模型处理非线性关系。

主要发现

  • 共纳入1466例患者,平均(标准差)年龄59.89(14.14)岁,女性占58.94%。
  • 加权平均血清25-羟基维生素D水平为59.26(24.99)nmol/l,38.95%的患者存在维生素D缺乏(或严重缺乏)(<50.00 nmol/l)。
  • 随访10453人年期间,记录268例全因死亡,其中心血管疾病(CVD)死亡52例、癌症死亡48例。
  • 与血清25-羟基维生素D <25.00 nmol/l的患者相比,血清25-羟基维生素D较高的患者全因死亡率较低。
  • 血清25-羟基维生素D与全因死亡率呈非线性L型关联,在血清25-羟基维生素D <37.30 nmol/l的患者中,血清25-羟基维生素D降低与全因死亡风险升高显著相关[HR 0.95 (0.92, 0.98); P < 0.01]。

临床怎么用

  • 作者认为应将血清25-羟基维生素D提升至一定水平以预防过早死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to examine the relationship between serum 25-hydroxyvitamin D and all-cause, cause-specific mortality of patients with RA. METHODS: This cohort study included 1466 patients with RA from The National Health and Nutrition Examination Survey (NHANES) 2001-14. Mortality status was obtained according to death certificate records from the National Death Index. Cox proportional risk models were used to estimate hazard ratios (HR) and 95% CI for mortality. A generalized additive model, smooth curve fitting and 2-piecewise Cox proportional hazards models were established to address the nonlinearity between serum 25-hydroxyvitamin D and mortality. RESULTS: A total of 1466 patients [mean (s.d.) 59.89 (14.14) years old; 58.94% female] were enrolled. The weighted mean level of 25-hydroxyvitamin D was 59.26 (24.99) nmol/l and 38.95% were found with deficient (or severe deficient) vitamin D (<50.00 nmol/l). During 10453 person-years of follow-up, 268 patients were documented for all-cause death, including 52 cardiovascular disease (CVD)deaths and 48 cancer deaths. Compared with patients with serum 25-hydroxyvitamin D <25.00 nmol/l, patients with higher serum 25-hydroxyvitamin D were more likely to have lower rate of all-cause mortality. Nonlinear and L-shaped association between serum 25-hydroxyvitamin D and all-cause mortality was found, and decreased serum 25-hydroxyvitamin D was significantly associated with increased risk of all-cause mortality in patients with serum 25-hydroxyvitamin D <37.30 nmol/l [HR 0.95 (0.92, 0.98); P < 0.01]. CONCLUSION: An L-shaped association between serum 25-hydroxyvitamin D and all-cause mortality was found among patients with RA, indicating that serum 25-hydroxyvitamin D should be improved to a certain level for the prevention of premature death.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cai B, Zhou M, Xiao Q, et al. L-shaped association between serum 25-hydroxyvitamin D and all-cause mortality of individuals with rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 35689616. doi:10.1093/rheumatology/keac341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。